MedTrace Logo

Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

NCT07313176 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 215

Last updated 2026-01-21

No results posted yet for this study

Summary

The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).

Conditions

  • Advanced Parkinson Disease

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

  • Britannia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Bharat Amlani, MPharm · Britannia Pharmacetuicals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2028-10-31
Completion
2029-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313176 on ClinicalTrials.gov